Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Jessica Ripepi"'
Autor:
Giovanni Palladini, Bruno Paiva, Ashutosh Wechalekar, Margherita Massa, Paolo Milani, Marta Lasa, Sriram Ravichandran, Isabel Krsnik, Marco Basset, Leire Burgos, Mario Nuvolone, Ramón Lecumberri, Andrea Foli, Noemi Puig, Melania Antonietta Sesta, Margherita Bozzola, Pasquale Cascino, Alice Nevone, Jessica Ripepi, Pierpaolo Berti, Simona Casarini, Ombretta Annibali, Alberto Orfao, Jesus San-Miguel, Giampaolo Merlini
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-7 (2021)
Abstract Light chain (AL) amyloidosis is caused by a small B-cell clone producing light chains that form amyloid deposits and cause organ dysfunction. Chemotherapy aims at suppressing the production of the toxic light chain (LC) and restore organ fun
Externí odkaz:
https://doaj.org/article/1af0c29e396946d49b7a958dc256ed9f
Autor:
Chiara Valsecchi, Stefania Croce, Alice Maltese, Lorenza Montagna, Elisa Lenta, Alice Nevone, Maria Girelli, Paolo Milani, Tiziana Bosoni, Margherita Massa, Carlotta Abbà, Rita Campanelli, Jessica Ripepi, Annalisa De Silvestri, Adriana Carolei, Giovanni Palladini, Marco Zecca, Mario Nuvolone, Maria Antonietta Avanzini
Publikováno v:
Biomedicines, Vol 9, Iss 11, p 1523 (2021)
Immunoglobulin light-chain amyloidosis (AL) is caused by misfolded light chains produced by a small B cell clone. Mesenchymal stromal cells (MSCs) have been reported to affect plasma cell behavior. We aimed to characterize bone marrow (BM)-MSCs from
Externí odkaz:
https://doaj.org/article/d9fdc9231c30407f882466b134b89c9b
Autor:
Jessica Ripepi, Chiara Valsecchi, Mario Nuvolone, Adriana Carolei, Alice Nevone, Marco Zecca, Margherita Massa, Paolo Milani, Maria Girelli, Alice Maltese, Annalisa De Silvestri, Stefania Croce, Giovanni Palladini, Rita Campanelli, Elisa Lenta, Carlotta Abbà, Lorenza Montagna, Tiziana Bosoni, Maria Antonietta Avanzini
Publikováno v:
Biomedicines
Volume 9
Issue 11
Biomedicines, Vol 9, Iss 1523, p 1523 (2021)
Volume 9
Issue 11
Biomedicines, Vol 9, Iss 1523, p 1523 (2021)
Immunoglobulin light-chain amyloidosis (AL) is caused by misfolded light chains produced by a small B cell clone. Mesenchymal stromal cells (MSCs) have been reported to affect plasma cell behavior. We aimed to characterize bone marrow (BM)-MSCs from
Autor:
Marco Basset, Paolo Milani, Virginia Valeria Ferretti, Mario Nuvolone, Andrea Foli, Francesca Benigna, Martina Nanci, Margherita Bozzola, Jessica Ripepi, Melania Sesta, Francesca Russo, Tiziana Bosoni, Catherine Klersy, Riccardo Albertini, Giampaolo Merlini, Giovanni Palladini
Publikováno v:
Clinical chemistry and laboratory medicineReferences. 60(3)
Objectives Quantification of 24 h-proteinuria is the gold standard for diagnosing, staging, and monitoring of patients with renal AL amyloidosis. However, 24 h-urine collection is cumbersome and may result in preanalytical error. In this prospective
Autor:
Ombretta Annibali, Marta Lasa, Mario Nuvolone, Leire Burgos, Pasquale Cascino, Isabel Krsnik, Sriram Ravichandran, Alice Nevone, Paolo Milani, Andrea Foli, Ashutosh D. Wechalekar, Jesús F. San-Miguel, Margherita Massa, Bruno Paiva, Ramón Lecumberri, Melania Antonietta Sesta, Giampaolo Merlini, Alberto Orfao, Pierpaolo Berti, Marco Basset, Simona Casarini, Margherita Bozzola, Giovanni Palladini, Jessica Ripepi, Noemi Puig
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-7 (2021)
Blood Cancer Journal
instname
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-7 (2021)
Blood Cancer Journal
© The Author(s) 2021.
Light chain (AL) amyloidosis is caused by a small B-cell clone producing light chains that form amyloid deposits and cause organ dysfunction. Chemotherapy aims at suppressing the production of the toxic light chain (LC) an
Light chain (AL) amyloidosis is caused by a small B-cell clone producing light chains that form amyloid deposits and cause organ dysfunction. Chemotherapy aims at suppressing the production of the toxic light chain (LC) an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e87246b18b34091d1e3d6be6bf093d22
http://hdl.handle.net/10261/261841
http://hdl.handle.net/10261/261841
Autor:
Giovanni Palladini, Margherita Massa, Enrico Milan, Mario Nuvolone, Melania Antonietta Sesta, Francesca Fazio, Alice Nevone, Andrea Foli, Giampaolo Merlini, Paolo Milani, Stefano Ricagno, Serena Caminito, Jessica Ripepi, Pasquale Cascino, Marica De Cicco, Paola Rognoni, Simona Casarini, Giulia Mazzini, Francesca Lavatelli, Margherita Bozzola, Gloria Acquafredda, Antonia Moretta, Giancarlo Russo, Maria Girelli, Marco Basset, Catherine Klersy, Claudia Scopelliti, Maria Teresa Petrucci
Publikováno v:
Blood. 138:2673-2673
Introduction In patients affected by monoclonal gammopathies, tumoral B cells or plasma cells secrete a monoclonal antibody (termed M protein), which can be used to track the presence of the tumor itself. Moreover, the M protein can directly cause po
Autor:
Giovanni Palladini, Jessica Ripepi, Margherita Bozzola, Marco Basset, Andrea Foli, Giampaolo Merlini, Mario Nuvolone, Paolo Milani
Publikováno v:
Blood. 134:3312-3312
Introduction: Autologous stem cell transplant (ASCT) is a very effective treatment in AL amyloidosis. However, its role is challenged by novel, powerful, non-transplant therapy, also due to the potentially high treatment-related mortality (TRM) that
Autor:
Alessandra Larocca, Maria Teresa Petrucci, Tamara Berno, Marco Basset, Andrea Foli, Stefania Oliva, Mario Nuvolone, Giampaolo Merlini, Francesca Fazio, Giovanni Palladini, Jessica Ripepi, Paolo Milani, Marcello Riva
Publikováno v:
Blood. 134:1860-1860
INTRODUCTION: Daratumumab has been recently introduced in the treatment of patients with multiple myeloma (MM). Two phase II trials of this drug in relapsed/refractory AL amyloidosis were recently completed, but final reports have not been published
Autor:
Mario Nuvolone, Jessica Ripepi, Margherita Bozzola, Andrea Foli, Giovanni Palladini, Paolo Milani, Giampaolo Merlini, Marco Basset
Publikováno v:
Blood. 134:1901-1901
Background: The International Society of Amyloidosis validated the criteria of hematologic response to therapy in AL amyloidosis, based on the reduction of free light chain (FLC) concentration and serum and urine immunofixation. Complete response (CR